Photodynamic Therapy Market
$6.97 Billion Photodynamic Therapy Market Outlook, 2024-2032, Featuring Detailed Analysis of Gladerma, Sun Pharmaceutical Industries, Biofrontera, Lumibird, Bausch Health Companies, and More
June 06, 2024 04:22 ET | Research and Markets
Dublin, June 06, 2024 (GLOBE NEWSWIRE) -- The "Photodynamic Therapy Market Report by Product Types, Application, End-user, Countries and Company Analysis 2024-2032" report has been added to ...
Arcutis logo.png
Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
June 05, 2024 08:00 ET | Arcutis Biotherapeutics, Inc.
Arcutis today announced that five abstracts will be presented at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago June 8-10.
Dermatology Collaboration and Licensing Deals Report, 2016 to 2024, Featuring 600+ Companies and 400+ Deals
May 02, 2024 07:33 ET | Research and Markets
Dublin, May 02, 2024 (GLOBE NEWSWIRE) -- The "Dermatology Collaboration and Licensing Deals 2016-2024" report has been added to's offering.Dermatology Collaboration and...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A TOP RANKED LAW FIRM, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VTYX
April 08, 2024 16:48 ET | The Rosen Law Firm PA
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant...
Sol Gel - New Logo - light.jpg
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
April 01, 2024 07:00 ET | Sol-Gel Technologies Ltd.
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
alumis logo.png
Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD Annual Meeting
March 09, 2024 12:00 ET | Alumis Inc
Alumis today announced the presentation of positive clinical data from a Phase 2 clinical trial of ESK-001 at AAD 2024.
STRATA Skin Sciences Logo.jpg
STRATA Skin Sciences Announces Initiative to Expand Treatment Coverage
March 07, 2024 08:00 ET | STRATA Skin Sciences, Inc.
HORSHAM, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and...
alumis logo.png
Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction
March 06, 2024 08:00 ET | Alumis Inc
– Financing led by Foresite Capital, Samsara BioCapital and venBio Partners with participation from additional new and existing investors –      – Proceeds will support ongoing comprehensive mid to...
alumis logo.png
Alumis Announces Late-Breaker Psoriasis Phase 2 Data Presentation for Allosteric TYK2 Inhibitor ESK-001 at the American Academy of Dermatology 2024 Annual Meeting
March 04, 2024 09:00 ET | Alumis Inc
– Late-breaking oral presentation to highlight efficacy and safety of ESK-001 in a Phase 2 clinical trial and open label extension (OLE) study in adults with moderate-to-severe plaque psoriasis...
Mind.Px test
Mindera Health™ Launches Program with Innovative Pharmacy Benefit Manager to Improve Management of Moderate-to-Severe Psoriasis Patients Through Precision Medicine
February 29, 2024 09:00 ET | Mindera Health
San Diego, CA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Mindera Health, developer of Mind.Px™, the first realization of precision medicine in psoriasis, has formed a partnership with Liviniti™, an...